These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1105 related articles for article (PubMed ID: 28619981)

  • 1. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
    Grommes C; Pastore A; Palaskas N; Tang SS; Campos C; Schartz D; Codega P; Nichol D; Clark O; Hsieh WY; Rohle D; Rosenblum M; Viale A; Tabar VS; Brennan CW; Gavrilovic IT; Kaley TJ; Nolan CP; Omuro A; Pentsova E; Thomas AA; Tsyvkin E; Noy A; Palomba ML; Hamlin P; Sauter CS; Moskowitz CH; Wolfe J; Dogan A; Won M; Glass J; Peak S; Lallana EC; Hatzoglou V; Reiner AS; Gutin PH; Huse JT; Panageas KS; Graeber TG; Schultz N; DeAngelis LM; Mellinghoff IK
    Cancer Discov; 2017 Sep; 7(9):1018-1029. PubMed ID: 28619981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
    Grommes C; Tang SS; Wolfe J; Kaley TJ; Daras M; Pentsova EI; Piotrowski AF; Stone J; Lin A; Nolan CP; Manne M; Codega P; Campos C; Viale A; Thomas AA; Berger MF; Hatzoglou V; Reiner AS; Panageas KS; DeAngelis LM; Mellinghoff IK
    Blood; 2019 Jan; 133(5):436-445. PubMed ID: 30567753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma.
    Grommes C; Nandakumar S; Schaff LR; Gavrilovic I; Kaley TJ; Nolan CP; Stone J; Thomas AA; Tang SS; Wolfe J; Bozza A; Wongchai V; Hyde A; Barrett E; Lynch EA; Madzsar JT; Lin A; Piotrowski AF; Pentsova E; Francis JH; Hatzoglou V; Schultz N; Reiner AS; Panageas KS; DeAngelis LM; Mellinghoff IK
    Clin Cancer Res; 2024 Sep; 30(18):4005-4015. PubMed ID: 38995739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.
    Bartlett NL; Costello BA; LaPlant BR; Ansell SM; Kuruvilla JG; Reeder CB; Thye LS; Anderson DM; Krysiak K; Ramirez C; Qi J; Siegel BA; Griffith M; Griffith OL; Gomez F; Fehniger TA
    Blood; 2018 Jan; 131(2):182-190. PubMed ID: 29074501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
    Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
    Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.
    Lionakis MS; Dunleavy K; Roschewski M; Widemann BC; Butman JA; Schmitz R; Yang Y; Cole DE; Melani C; Higham CS; Desai JV; Ceribelli M; Chen L; Thomas CJ; Little RF; Gea-Banacloche J; Bhaumik S; Stetler-Stevenson M; Pittaluga S; Jaffe ES; Heiss J; Lucas N; Steinberg SM; Staudt LM; Wilson WH
    Cancer Cell; 2017 Jun; 31(6):833-843.e5. PubMed ID: 28552327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
    Advani RH; Buggy JJ; Sharman JP; Smith SM; Boyd TE; Grant B; Kolibaba KS; Furman RR; Rodriguez S; Chang BY; Sukbuntherng J; Izumi R; Hamdy A; Hedrick E; Fowler NH
    J Clin Oncol; 2013 Jan; 31(1):88-94. PubMed ID: 23045577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms.
    Roskoski R
    Pharmacol Res; 2016 Nov; 113(Pt A):395-408. PubMed ID: 27641927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
    Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
    Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.
    Smith CIE; Burger JA
    Front Immunol; 2021; 12():689472. PubMed ID: 34177947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.
    Ma J; Lu P; Guo A; Cheng S; Zong H; Martin P; Coleman M; Wang YL
    Br J Haematol; 2014 Sep; 166(6):849-61. PubMed ID: 24957109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
    Sharma S; Galanina N; Guo A; Lee J; Kadri S; Van Slambrouck C; Long B; Wang W; Ming M; Furtado LV; Segal JP; Stock W; Venkataraman G; Tang WJ; Lu P; Wang YL
    Oncotarget; 2016 Oct; 7(42):68833-68841. PubMed ID: 27626698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy.
    Fox LC; Yannakou CK; Ryland G; Lade S; Dickinson M; Campbell BA; Prince HM
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29899297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.
    Molina-Cerrillo J; Alonso-Gordoa T; Gajate P; Grande E
    Cancer Treat Rev; 2017 Jul; 58():41-50. PubMed ID: 28641100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
    Hong D; Rasco D; Veeder M; Luke JJ; Chandler J; Balmanoukian A; George TJ; Munster P; Berlin JD; Gutierrez M; Mita A; Wakelee H; Samakoglu S; Guan S; Dimery I; Graef T; Borazanci E
    Oncology; 2019; 97(2):102-111. PubMed ID: 31230047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ibrutinib: A new drug of B-cell malignancies].
    Thieblemont C
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introduction of novel agents in the treatment of primary CNS lymphoma.
    Grommes C; Nayak L; Tun HW; Batchelor TT
    Neuro Oncol; 2019 Feb; 21(3):306-313. PubMed ID: 30423172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
    Lim KJC; Tam CS
    Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    Wang ML; Rule S; Martin P; Goy A; Auer R; Kahl BS; Jurczak W; Advani RH; Romaguera JE; Williams ME; Barrientos JC; Chmielowska E; Radford J; Stilgenbauer S; Dreyling M; Jedrzejczak WW; Johnson P; Spurgeon SE; Li L; Zhang L; Newberry K; Ou Z; Cheng N; Fang B; McGreivy J; Clow F; Buggy JJ; Chang BY; Beaupre DM; Kunkel LA; Blum KA
    N Engl J Med; 2013 Aug; 369(6):507-16. PubMed ID: 23782157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.